Engineered immune cells take on tough autoimmune diseases

NCT ID NCT07473154

Recruiting now Disease control Sponsor: Quell Therapeutics Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This early-stage trial tests an experimental treatment called QEL-005 for people with two serious autoimmune conditions: diffuse cutaneous systemic sclerosis and difficult-to-treat rheumatoid arthritis. QEL-005 is made from a patient's own white blood cells, which are genetically modified in a lab to become special immune cells that target and calm overactive parts of the immune system. The study aims to check if the treatment is safe and tolerable, and to see if it can reduce disease activity. Participants will receive a single infusion of their modified cells and be followed for 15 years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE RHEUMATOLOGIC DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse cutaneous systemic sclerosis diffuse scleroderma rheumatoid arthritis systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE RHEUMATOLOGIC DISEASE DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS RHEUMATOID ARTHRITIS (RA) SYSTEMIC SCLEROSIS (SSC)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Guy's & St Thomas NHS Foundation Trust
NOT_YET_RECRUITING

London, United Kingdom
Leeds Teaching Hospitals NHS Trust
RECRUITING

Leeds, United Kingdom
Newcastle Upon Tyne NHS Foundation Trust
RECRUITING

Newcastle, United Kingdom
Royal Free London NHS Foundation Trust
NOT_YET_RECRUITING

London, United Kingdom
University Hospitals Birmingham NHS Foundation Trust
RECRUITING

Birmingham, United Kingdom

Contact Email: •••••@•••••
University of Oxford - The Kennedy Institute
RECRUITING

Oxford, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.